Assessment of Adverse Events and Their Ability to Discriminate Response to Anti-PD-1/PD-L1 Antibody Immunotherapy

J Clin Oncol. 2020 Jan 1;38(1):103-104. doi: 10.1200/JCO.19.01712. Epub 2019 Nov 1.

Authors

Howard L McLeod¹, Arshiya Mariam¹, Kimberly A Schveder¹, Daniel M Rotroff¹

Affiliation

¹ Howard L. McLeod, PharmD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; and Arshiya Mariam, Kimberly A. Schveder, and Daniel M. Rotroff, PhD, MSPH, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.

PMID: 31675248
DOI: 10.1200/JCO.19.01712

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies
B7-H1 Antigen*
Humans
Immunotherapy*

Substances

Antibodies
B7-H1 Antigen

Grants and funding

KL2 TR002547/TR/NCATS NIH HHS/United States